ADMA Biologics Inc logo

ADMA Biologics Inc(ADMA)

Top Performer Top performer
upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL RECENCY
4-STAR RATING
STRONG BUY
BUY for 38 days
PROFIT SINCE LAST BUY
+31.31% ▲
LAST CLOSE
$13.17
11/20/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for ADMA

11/20/2026: ADMA (4-star) is a STRONG-BUY. BUY for 38 days. Simulated Profits (31.31%). Updated daily EoD!

ADMA Biologics is a commercial biopharmaceutical company specializing in plasma-derived therapeutics for immunodeficient patients. The company's main strengths reside in its proprietary manufacturing facility and strong sales execution for its flagship product, ASCENIV. Its primary growth story centers on expanding production yields and increasing physician adoption to achieve ambitious multi-year revenue targets. Key risks include intense competition from global plasma giants and potential manufacturing concentration vulnerabilities. The stock suits growth-oriented investors willing to monitor operational execution and regulatory consistency.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fitThe company exhibits robust multi-year revenue expansion and high forward growth targets.
Momentum investorStrong fit while signal remains positivePositive earnings beats and upward revisions can trigger strong momentum trends when technical sentiment aligns.
Value investorMixed fitWhile profitability has turned robust, valuation multiples reflect expectations for continued rapid expansion.
Dividend investorWeak fitADMA does not pay dividends, retaining earnings to fuel corporate expansion.
Low-risk investorWeak fitBiopharmaceutical execution risks and market volatility make it less suitable for conservative capital.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityMedium / highBiotech equities frequently experience sharper sentiment-driven swings than broader market indices.
Valuation riskMediumSustained high multiples leave little room for operational missteps or guidance misses.
Competition risk (plasma fractionation dominance)HighThe market is heavily dominated by entrenched global giants with vast capital resources.
Business qualityMedium / highProprietary manufacturing assets and rising margins indicate solid foundational quality.
Dividend incomeLow / noneNo payouts are offered as cash is prioritized for internal reinvestment.
Execution riskMedium / highMeeting ambitious long-term financial targets requires flawless operational delivery.

Key Highlights

Company Size Mid-Cap Stock
Market Capitalization 2.92B USD
Price to earnings Ratio 17.1
1Y Target Price 18
Price to earnings Ratio 17.1
1Y Target Price 18
Volume (30-day avg) 3.7M shares
Beta 0.66
52 Weeks Range 7.21 - 20.46
Updated Date 11/20/2026
52 Weeks Range 7.21 - 20.46
Updated Date 11/20/2026
Dividends yield (FY) -
Basic EPS (TTM) 0.77

Sector & Industry Intelligence

Sector

Healthcare

Constructive
Sentiment
Strong Bullish
Momentum
BUY Breadth Improving
BUY participation
55.2%
Active BUY / eligible
53 / 96
30-Day BUY Count Change
+19
Market state
Strong Bullish

More qualifying stocks are receiving or maintaining BUY advisories, indicating improving market participation.

Industry

Biotechnology

BUY participation
43.2%
Active BUY / eligible
19 / 44
30-Day BUY Count Change
+12

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Downtrend
PRICE PATH

Downtrend

The stock has experienced a sustained decline in price over recent periods.

Choppy
PRICE STABILITY

Choppy

The stock has experienced frequent reversals and pronounced short-term price swings.

Analysis of Past Performance

Type Stock
Historic Profit 197.49%
Avg. Invested days 45
Today’s Advisory Strong Buy
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 4.0
Stock Returns Performance Upturn Returns Performance icon 5.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/20/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
ADMA receives a 4-star rating, supported by solid unit economics, and solid company fundamentals. The rating is constrained by weak price momentum.

Company Fundamentals

★★★★★
ADMA has solid overall fundamentals (4 stars), with solid financial health, moderate growth momentum, and solid ownership. In FY2025 versus FY2024, solid cash generation (FCF margin 5.5%) and solid revenue growth (+19.6%) are partially offset by negative earnings growth (-25.7%), modest insider ownership of 1.97%.

Financial Health Rating

★★★★★
ADMA's financial health is supported by solid profitability, including gross margin of 57.4% and operating margin of 37.5%. Overall financial-health metrics support a 4-star score.

Growth Momentum Score

★★★★★
Revenue growth is ADMA's strongest growth driver at +19.6% FY2025 versus FY2024 (solid, 4 stars). By comparison, while earnings growth (-25.7%, negative) and free-cash-flow growth (-74.7%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 92.9% and approximately 92.5% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 1.97% provides only moderate management-shareholder alignment.

Top 5 Institutional Investors

BlackRock Inc 17.29%
State Street Corp 7.72%
Vanguard Capital Management, LLC 4.55%
Vanguard Portfolio Management, LLC 4.55%
Rubric Capital Management LP 4.21%

Unit Economics (Per $1K Revenue)

★★★★★
ADMA generates approximately $574 of gross profit, $375 of operating income, and $55 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Solid margins, cash conversion, and capital efficiency support the rating.

Economic Dimensions

★★★★★
Effective Tax Rate: 19.56%

Quantitative Style Profile

★★★★★
ADMA has a high-quality, liquid, relatively low-volatility profile. Weak momentum is the primary drawback, while valuation that is moderately attractive rather than deeply discounted.

Style Classification

Quality Focused

Quality TiltLow VolatilitySmall / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
ADMA BioManufacturingRevenues derived from the sale of specialty plasma-derived biologics including ASCENIV, BIVIGAM, and NABI-HB.This is the core profit engine where the company turns raw plasma into high-value immune therapeutics.
Plasma Collection CentersRevenues from plasma collection centers and intermediate fraction sales.Supports raw material supply security and supplemental operational revenue.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date 2026-11-04
When After Market
Estimate 0.19
Actual 0.22

Profitability

Profit Margin 35.14%
Operating Margin (TTM) 44.93%

Management Effectiveness

Return on Assets (TTM) 22.41%
Return on Equity (TTM) 41.95%

Valuation

Trailing PE 17.1
Forward PE 13.61
Enterprise Value 3.04B
Price to Sales(TTM) 5.63
Enterprise Value 3.04B
Price to Sales(TTM) 5.63
Enterprise Value to Revenue 5.85
Enterprise Value to EBITDA 12.03
Shares Outstanding 221.85M
Shares Floating 205.22M
Shares Outstanding 221.85M
Shares Floating 205.22M
Percent Insiders 1.97
Percent Institutions 92.94

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.